MX2018005261A - Faecalibacterium prausnitzii y desulfovibrio piger para usarse en el tratamiento o prevencion de diabetes y enfermedades intestinales. - Google Patents
Faecalibacterium prausnitzii y desulfovibrio piger para usarse en el tratamiento o prevencion de diabetes y enfermedades intestinales.Info
- Publication number
- MX2018005261A MX2018005261A MX2018005261A MX2018005261A MX2018005261A MX 2018005261 A MX2018005261 A MX 2018005261A MX 2018005261 A MX2018005261 A MX 2018005261A MX 2018005261 A MX2018005261 A MX 2018005261A MX 2018005261 A MX2018005261 A MX 2018005261A
- Authority
- MX
- Mexico
- Prior art keywords
- faecalibacterium prausnitzii
- prevention
- treatment
- diabetes
- bowel diseases
- Prior art date
Links
- 241000605980 Faecalibacterium prausnitzii Species 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 2
- 241000604463 Desulfovibrio piger Species 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 abstract 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000006041 probiotic Substances 0.000 abstract 1
- 230000000529 probiotic effect Effects 0.000 abstract 1
- 235000018291 probiotics Nutrition 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
La presente invención se refiere de manera general a medicina. Más específicamente la invención se refiere al uso de bacterias probióticas sinérgicas como intervención para la salud. En particular, la presente invención proporciona una cepa de Faecalibacterium prausnitzii y una cepa bacteriana la cual tiene una o más de las características de: (i) ser productora de acetato, (ii) ser consumidora de lactato y (iii) tener la capacidad de ser un aceptor de electrones, para usarse en el tratamiento o prevención de una enfermedad asociada con niveles de butirato reducidos o una enfermedad asociada con números reducidos o bajos de bacterias Faecalibacterium prausnitzii.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1519088.7A GB201519088D0 (en) | 2015-10-28 | 2015-10-28 | The use of bacteria formulations |
| PCT/EP2016/076038 WO2017072278A1 (en) | 2015-10-28 | 2016-10-28 | Faecalibacterium prausnitzii and desulfovibrio piger for use in the treatment or prevention of diabetes and bowel diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018005261A true MX2018005261A (es) | 2019-07-04 |
Family
ID=55130365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018005261A MX2018005261A (es) | 2015-10-28 | 2016-10-28 | Faecalibacterium prausnitzii y desulfovibrio piger para usarse en el tratamiento o prevencion de diabetes y enfermedades intestinales. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11260082B2 (es) |
| EP (1) | EP3368053A1 (es) |
| JP (1) | JP7018396B2 (es) |
| KR (2) | KR20180070698A (es) |
| CN (2) | CN115778986A (es) |
| AU (1) | AU2016344770B2 (es) |
| BR (1) | BR112018008312B1 (es) |
| CA (1) | CA3002603A1 (es) |
| CL (1) | CL2018001133A1 (es) |
| GB (1) | GB201519088D0 (es) |
| HK (1) | HK1257739A1 (es) |
| IL (1) | IL258881B2 (es) |
| MX (1) | MX2018005261A (es) |
| RU (1) | RU2754367C2 (es) |
| SG (1) | SG11201803062XA (es) |
| WO (1) | WO2017072278A1 (es) |
| ZA (1) | ZA201802585B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11959125B2 (en) * | 2016-09-15 | 2024-04-16 | Sun Genomics, Inc. | Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample |
| CN111107860A (zh) * | 2017-06-16 | 2020-05-05 | 表飞鸣制药株式会社 | 脂肪相关疾病和/或炎症的预防或治疗剂 |
| EP3665181A4 (en) * | 2017-08-07 | 2021-06-09 | Finch Therapeutics, Inc. | COMPOSITIONS AND PROCEDURES FOR DECOLONIZATION OF ANTIBIOTIC-RESISTANT BACTERIA IN THE INTESTINAL |
| US11491192B2 (en) | 2018-01-09 | 2022-11-08 | The Cleveland Clinic Foundation | Treatment and prevention of pathogenic bacterial overgrowth using butyrate-producing bacteria |
| WO2020064764A1 (en) * | 2018-09-25 | 2020-04-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of mam polypeptides for the treatment of obesity and obesity-related disorders |
| CN110878349A (zh) * | 2019-12-06 | 2020-03-13 | 深圳谱元科技有限公司 | 终末期肾病生物标志物及其应用 |
| EP3858363A1 (en) * | 2020-01-28 | 2021-08-04 | Institut national de recherche pour l'agriculture, l'alimentation et l'environnement | Composition for treating intestinal or pulmonary diseases |
| NL2025020B1 (en) * | 2020-02-28 | 2021-10-14 | Acad Medisch Ct | Intervention strategy for prevention or treatment of autoimmune diseases |
| KR102169794B1 (ko) * | 2020-06-24 | 2020-10-27 | 주식회사 엔테로바이옴 | 신규한 피칼리박테리움 프로스니치 균주 eb-fpdk11 및 그의 용도 |
| KR102169795B1 (ko) * | 2020-06-24 | 2020-10-27 | 주식회사 엔테로바이옴 | 신규한 피칼리박테리움 프로스니치 eb-fpdk9 균주 및 그의 용도 |
| KR102185828B1 (ko) | 2020-08-26 | 2020-12-03 | 주식회사 엔테로바이옴 | 피칼리박테리움 프로스니치 균주를 포함하는 아토피성 질환 예방 또는 치료용 약학적 조성물 |
| KR102245415B1 (ko) * | 2020-12-14 | 2021-04-29 | 주식회사 엔테로바이옴 | 피칼리박테리움 프로스니치 균주 배양 배지 조성물 |
| WO2022233922A1 (en) * | 2021-05-06 | 2022-11-10 | Société des Produits Nestlé S.A. | Compositions and methods using at least one of inositol, erythritol or sorbitol to enhance growth of faecalibacterium prausnitzii |
| CN113201575A (zh) * | 2021-05-11 | 2021-08-03 | 西安医学院第一附属医院 | 基于普氏粪杆菌对动物肾脏炎症反应变化影响的研究方法 |
| CN113797232B (zh) * | 2021-10-28 | 2023-05-26 | 南昌大学 | 具有缓解胰岛素抵抗功能的组合物及其应用 |
| CN114304380A (zh) * | 2022-01-13 | 2022-04-12 | 合肥河川生物医药科技有限公司 | 普拉梭菌在猪鸡上的应用 |
| CN117384867A (zh) * | 2022-09-16 | 2024-01-12 | 北京普译生物科技有限公司 | 一种经修饰的Cas3移位酶及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ899700A0 (en) * | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| CA2854398A1 (en) * | 2011-11-04 | 2013-05-10 | General Mills, Inc. | Methods and compositions for modulating gastrointestinal bacteria to promote health |
| US9314494B2 (en) * | 2012-05-25 | 2016-04-19 | The United States Of America, As Represented By The Secretary Of Agriculture | Cranberry xyloglucan oligosaccharide composition |
| US8906668B2 (en) * | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| EP2988761A1 (en) | 2013-03-05 | 2016-03-02 | Rijksuniversiteit Groningen | Use of faecali bacterium prausnitzii htf-f (dsm 26943) to suppress inflammation. |
| CN105120847B (zh) * | 2013-03-14 | 2018-12-28 | 塞拉拜姆有限责任公司 | 益生生物和/或治疗剂的靶向胃肠道递送 |
| US20150246081A1 (en) * | 2014-03-03 | 2015-09-03 | Shayne Kenneth Morris | Probiotics with methods for growth and use separately and in combination |
-
2015
- 2015-10-28 GB GBGB1519088.7A patent/GB201519088D0/en not_active Ceased
-
2016
- 2016-10-28 CA CA3002603A patent/CA3002603A1/en active Pending
- 2016-10-28 KR KR1020187015001A patent/KR20180070698A/ko not_active IP Right Cessation
- 2016-10-28 JP JP2018541515A patent/JP7018396B2/ja active Active
- 2016-10-28 US US15/771,619 patent/US11260082B2/en active Active
- 2016-10-28 EP EP16788507.8A patent/EP3368053A1/en active Pending
- 2016-10-28 BR BR112018008312-7A patent/BR112018008312B1/pt active IP Right Grant
- 2016-10-28 WO PCT/EP2016/076038 patent/WO2017072278A1/en active Application Filing
- 2016-10-28 MX MX2018005261A patent/MX2018005261A/es unknown
- 2016-10-28 CN CN202310015135.4A patent/CN115778986A/zh active Pending
- 2016-10-28 IL IL258881A patent/IL258881B2/en unknown
- 2016-10-28 SG SG11201803062XA patent/SG11201803062XA/en unknown
- 2016-10-28 AU AU2016344770A patent/AU2016344770B2/en active Active
- 2016-10-28 KR KR1020207037542A patent/KR102371868B1/ko active IP Right Grant
- 2016-10-28 CN CN201680063240.3A patent/CN108367030B/zh active Active
- 2016-10-28 RU RU2018119309A patent/RU2754367C2/ru active
-
2018
- 2018-04-18 ZA ZA2018/02585A patent/ZA201802585B/en unknown
- 2018-04-27 CL CL2018001133A patent/CL2018001133A1/es unknown
-
2019
- 2019-01-04 HK HK19100113.1A patent/HK1257739A1/zh unknown
-
2022
- 2022-01-17 US US17/577,208 patent/US20220133814A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018005261A (es) | Faecalibacterium prausnitzii y desulfovibrio piger para usarse en el tratamiento o prevencion de diabetes y enfermedades intestinales. | |
| MX2019009132A (es) | Composiciones bacterianas sinergicas y sus metodos de produccion y usos. | |
| NZ722185A (en) | Alpha (1,2) fucosyltransferase syngenes for use in the production of fucosylated oligosaccharides | |
| NZ711771A (en) | Compositions for treating or preventing or reducing the severity of clostridium difficile related diseases | |
| MX2016002765A (es) | Empleo de una composicion que comprende microorganismos para aumentar la produccion intestinal de acido butirico, acido folico o niacina y/o disminuir la produccion intestinal de acido succinico. | |
| EA201792547A1 (ru) | Популяции бактерий для стимуляции состояния здоровья | |
| BR112013000097A2 (pt) | composições e métodos relacionados a variantes da proteína a (spa) | |
| BR112012033212A2 (pt) | uso de lactobacillo inibindo a produção de gás de bactéria coliforme isolada em infantes afetados por cólica | |
| WO2019066577A3 (ko) | 짧은 사슬 지방산 생성 장내 세균 군집의 변화를 이용한 알코올성 간 질환의 진단 및 치료용 조성물 | |
| MX353230B (es) | Un bacteriofago para biocontrol de salmonella y en la preparacion o procesamiento de alimentos. | |
| BR112017015876A2 (pt) | microrganismos geneticamente modificados que apresentam tolerância melhorada à l-serina | |
| GB2564514A (en) | Health supplements | |
| MX2014005765A (es) | Compuestos triciclicos, composiciones que los comprenden y usos de los mismos. | |
| EA201991301A1 (ru) | Урогенитальная композиция для медицинского устройства на основе подходящих биохимических композиций для стабилизации кислотности и редокс-состояния вагинальной жидкости | |
| IN2012DN06392A (es) | ||
| MX369176B (es) | Composiciones fitoquímicas útiles como desinfectantes y conservadores para alimentos. | |
| PH12019501439A1 (en) | Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus | |
| NZ705406A (en) | Use of attenuated strains of toxoplasma for the prevention or treatment of cryptosporidiosis | |
| BR112014004123A2 (pt) | micro-organismos das espécies bacteroides xylanisolvens | |
| MX2023005014A (es) | Metodos de tratamiento de enfermedades inflamatorias cronicas. | |
| Stankevich et al. | The use of ozone technologies in maintaining the necessary sanitary conditions of production facilities | |
| Medvedev et al. | NTIBIOTIC STEWARDSHIP PROGRAM REDUCES THE USAGE AND COSTS OF SYSTEMIC ANTIBIOTICS AND LOWERS IN-HOSPITAL MORTALITY | |
| Arroyave et al. | Characterization of an Acinectobacter baumannii infection outbreak at San José University Hospital, Popayán, Colombia | |
| MX358790B (es) | Composición bactericida e inductora de resistencia de origen orgánico para la prevención, control y/o eliminación de enfermedades fitopatógenas en cultivos agrícolas. | |
| Babinets et al. | Optimization proand antioxidant status of patient with chronic pancreatitis under the influence of dynamic electroneurostimulation |